The New England journal of medicine
-
Comment Letter
HIV Infection - Screening, Diagnosis, and Treatment. Reply.
-
Comment Letter
Targeted Temperature Management after Cardiac Arrest. Reply.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells. ⋯ Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. (Funded by Immunocore; ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.).